RT Journal Article
SR Electronic
T1 Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.29.21254534
DO 10.1101/2021.03.29.21254534
A1 Marchi, S
A1 Viviani, S
A1 Remarque, EJ
A1 Ruello, A
A1 Bombardieri, E
A1 Bollati, V
A1 Milani, GP
A1 Manenti, A
A1 Lapini, G
A1 Rebuffat, A
A1 Montomoli, E
A1 Trombetta, CM
YR 2021
UL http://medrxiv.org/content/early/2021/03/31/2021.03.29.21254534.abstract
AB SARS-CoV-2 pandemic is causing high morbidity and mortality burden worldwide with unprecedented strain on health care systems.To elucidate the mechanism of infection, protection, or rapid evolution until fatal outcome of the disease we performed a study in hospitalized COVID-19 patients to investigate the time course of the antibody response in relation to the outcome. In comparison we investigated the time course of the antibody response in SARS-CoV-2 asymptomatic subjects.Study results show that patients produce a strong antibody response to SARS-CoV-2 with high correlation between different viral antigens (spike protein and nucleoprotein) and among antibody classes (IgA, IgG, and IgM and neutralizing antibodies). The peak is reached by 3 weeks from hospital admission followed by a sharp decrease. No difference was observed in any parameter of the antibody classes, including neutralizing antibodies, between subjects who recovered or with fatal outcome. Only few asymptomatic subjects developed antibodies at detectable levels.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by a research grant (Pfizer Tracking Number 60353289). This funding source did not have any role in the design of this study and during its execution, analyses, interpretation of the data, or decision to submit results. This study was supported by the European Virus Archive goes Global (EVAg) project, which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 653316. The UNICORN population was recruited thanks to the Funding Action Ricerche Emergenza coronavirus, University of Milan, 2020. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the University of Siena (approval number 17373, approval date June 1, 2020), by the Ethics Committee of Humanitas Gavazzeni (approval number 236, approval date September 22, 2020 Protocol 670/20). The UNICORN study was approved by the Ethics Committee of the University of Milan (approval number 17/20, approval date March 6, 2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing not applicable. No new data were created or analyzed in this study.